韩成芳. 药品专利制度的现实困境及反思[J]. 科技进步与对策, 2021, 38(15): 118-124.
Han Chengfang. Realistic Dilemma and Reflection of Drug Patent System. SCIENCE & TECHNOLOGY PROGRESS AND POLICY, 2021, 38(15): 118-124.
[1] [美]菲利普·希尔茨. 保护公众健康：美国食品药品百年监管历程[M]. 姚明威，译. 北京：中国水利水电出版社，2005: 97-98. [2] [美]唐纳德·R，基尔希，[美]奥吉·奥加斯. 猎药师：发现新药的人[M]. 陶亮，译. 北京：中信出版社，2019: 222-223. [3] HENRY B. Drug pricing & challenges to hepatitis c treatment access[J]. Journal of Health & Biomedical Law,2018,14:265-283. [4] JAMES ALLEN KODAK. Drug patent purchasing: a potent means of lowering drug prices while encouraging innovation[J]. Quinnipiac Health Law Journal, 2009, 13: 39.[5] 丁锦希. 创新药物研发政策解读与战略管理[M]. 南京：江苏科学技术出版社，2012: 15. [6] N NICOLE STAKLEFF. A drug life: the chemistry of patent and regulatory exclusivity for pharmceuticals[J]. Florida Coastal Law Review, 2014, 16: 27.[7] JAMES BESSEN, MICHAEL J MEURER. Patent failure: how judges, bureaucrats, and lawyers put innovators at risk[M]. United Kingdom: Princeton University Press, 2008: 6.[8] BRETT HAVRANEK. Pharmaceutical patents, paragraph iv, and pay-for-delay: the landscape of drug patent litigation and the lessons provided for the recently passed biosimilar approval pathway[J]. Intellectual Property Brief, 1: 16.[9] JACLYN L. MILLER. Drug price competition and patent term restoration act: the elimination of competition between drug manufacturers[J]. DePaul Journal of Health Care Law, 2002, 5(1): 95-104.[10] 彭雷. 极简新药发现史[M]. 北京：清华大学出版社，2018: 323-324. [11] [美]巴特菲，[英]李. 药物发现的未来：谁来决定治疗哪些疾病[M]. 王明伟，等，译. 北京：科学出版社，2014: 2. [12] 雷朝霞. 论知识霸权及其应对：以TRIPS、TRIPS-plus协议中的专利相关制度为中心[M]. 北京：中国社会科学出版社，2017: 21-23. [13] [美]苏珊·K，塞尔. 私权、公法——知识产权的全球化[M]. 董刚，周超，译. 北京：中国人民大学出版社，2008: 47-49. [14] 何华. 知识产权全球治理体系的功能危机与变革创新:基于知识产权国际规则体系的考察[J]. 政法论坛,2020,38(3):66-79.[15] 朱怀祖. 药品专利强制许可研究[M]. 北京：知识产权出版社，2011: 111-112. [16] 何隽. 创新驱动的知识产权政策[M]. 北京：知识产权出版社，2018: 29. [17] [英]克里斯汀·格林哈尔希，[英]马克·罗格. 创新、知识产权与经济增长[M]. 刘劭君，李维光，译.北京：知识产权出版社，2017: 4-7. [18] [美]罗伯特·P，莫杰思. 知识产权正当性解释[M]. 金海军，史兆欢，寇海侠，译. 北京：商务印书馆，2019: 502. [19] MERRILL GOOZNER. The $800 million pill : the truth behind the cost of new drugs[M]. United States: University of California Press, 2004: 231. [20] D HARRIS, HERMANN K, BAWA R, et al. Strategies for resolving patent disputes over nanoparticle drug delivery systems[J]. Nanotechnology Law & Business, 2004, 1: 372.[21] PHEBE HONG,AARON S KESSELHEIM,AMEET SARPATWARI, et al. Transformative models to promote prescription drug innovation and access: a landscape analysis[J]. Yale Journal of Health Policy, 2020, 19(2): 56-95. [22] FELDMAN R. May your drug price be evergreen[J].Journal of Law and the Biosciences,2018,5(3):590-647.[23] HANNAH BRENNAN et al. A prescription for excessive drug pricing: leveraging government patent use for health[J]. Yale Journal of Law and Technology, 2016, 18: 275.[24] DAN L BURK, MARK A LEMLEY. The patent crisis and how the courts can solve it[M]. United States: The University of Chicago Press, 2009: 7-8. [25] SIDDARTHA RAO. Closing the global drug gap: a pragmatic approach to the problem of access to medicines[J]. Journal of Legal Technology Risk Management, 2008, 3(2): 1-2.[26] PRABHU RAM. India's new TRIPS-complaint patent regime between drug patents and the right to health[J]. Chicago-Kent Journal of Intellectual Property, 2005-2006, 5: 195.[27] 冯洁菡. 公共健康与知识产权国际保护问题研究[M]. 北京：中国社会科学出版社，2012: 9. [28] 袁红梅，杨舒杰. 药品知识产权以案说法[M]. 北京：人民卫生出版社，2015: 164. [29] [法]米克尔·博尔奇-雅各布森. 大制药时代[M]. 朱沁，译. 太原：山西经济出版社，2016: 61-62. [30] [美]劳伦斯·O，戈斯廷. 全球卫生法[M]. 翟宏丽，译. 北京：中国政法大学出版社，2016: 378. [31] 梁贵柏. 新药研发的故事[M]. 上海：上海三联书店，2014: 11-23. [32] 中国药学会. 中国创新药物研发战略研究报告:2014-2015[M]. 西安:第四军医大学出版社,2016:11.[33] 中国生物技术发展中心. 中国现代医学科技创新能力国际比较[M]. 北京：中国医药科技出版社，2009: 20. [34] [美]梅雷迪丝·瓦德曼. 疫苗竞赛：人类对抗疾病的代价[M]. 罗爽，译. 南京：译林出版社，2020: 376-380. [35] 姚颉靖. 全球视野下的药品专利：从利益分配到利益创造[M]. 北京：知识产权出版社，2011:162.
